Tamam Bakchoul "Clinical Manifestations"
This presentation will highlight the pathophysiology of HIT, emphasizing characteristic clinical features. In addition, a summary of current therapeutic options for patients with HIT will be provided.
Ismail Elalamy "Laboratory Measurement"
HIT diagnosis remains a clinical challenge. There is no gold standard or certainty criteria so practitioners have to establish HIT diagnosis based on greater imputability. In fact, practitioners have to reinforce the probability of this etiology to be convinced and secure optimally the patient journey.
HIT diagnosis is prospectively built on both functional and immunological assays. The recent technical progress allowed new tests more rapid, more accurate, more simple, more accessible but their use must be well understood and well combined to improve HIT management. This presentation will review the advantages and limits of all these assays to draw the best way of HIT diagnosis in 2016: practical, useful and reliable.
Moderator: Ketan Kulkarni
This meeting is being supported by Instrumentation Laboratory
- All doctors and scientists using heparin
- Physicians heparin prescribers
- Anesthesiologists suspecting HIT
- Biologists detecting HIT
- Students learning HIT
At the end of this Webinar, the participants will be able to:
- Establish differential diagnosis for acquired thrombocytopenia
- Select appropriate upfront management of heparin-induced thrombocytopenia (HIT)
- Discuss treatment options for patients who are suspected to have HIT
- Know all the assays characteristics : limits and advantages
- Identify the best sequence for their potential combination
- Define a well-informed diagnosis strategy
- See right and do right to decide right
Tamam Bakchoul "Clinical Manifestations"
Ismail Elalamy "Laboratory Measurement"
Moderator: Ketan Kulkarni, IWK Health Centre (Canada)
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:
Name | Company | Role |
Geoffrey Barnes, MD | Portola | Consulting |
Blue Cross Blue Shield of Michigan | Research | |
BMS/Pfizer | Research | |
Chris Ward, PhD | Bayer | Speaker |
Boehringer-Ingelheim | Speaker, Advisory Board | |
BMS/Pfizer | Speaker, Advisory Board | |
Yukio Ozaki | The Sysmex Corporation | Advisory Board |
Contact
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.